论文部分内容阅读
Cefixime是新开发的第三代口服头孢菌素,抗菌谱不同于目前常用口服噻吩类头孢菌素,特别是对革蓝氏阴性菌,如大肠杆菌、流感嗜血杆菌、淋病奈瑟氏球菌和吲哚阳性变形菌等具有强大的抗菌活性,对口服噻吩类头孢菌素耐药菌株也敏感。而且对β-内酰胺酶也非常稳定。该药的药代动力学特点是半衰期较长,明显延长了血中有效药浓度,每天给药1次或2次即可达到有效治疗。比较治疗在双盲条件下进行。60冽下呼吸道感染,主要为急性支气管炎,随机分为两组。Cefixime治疗组24例,女性6例,男
Cefixime is a newly developed third-generation oral cephalosporin. The antibacterial spectrum is different from the commonly used oral thiophene-type cephalosporins, especially for Gram-negative bacteria such as Escherichia coli, Haemophilus influenzae, Neisseria gonorrhoeae and Indole positive Proteus has a strong antibacterial activity, oral administration of thiophene-resistant cephalosporins strains are also sensitive. And β-lactamase is also very stable. Pharmacokinetics of the drug is characterized by a longer half-life, significantly prolong the effective concentration of blood drug administration once or twice daily to achieve effective treatment. Comparison of treatment in double-blind conditions. 60 冽 lower respiratory tract infection, mainly acute bronchitis, were randomly divided into two groups. Cefixime treatment group of 24 patients, 6 females, male